CYCN (Cyclerion Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CYCN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Regina Margaret Graul | See Remarks | MIXED | — | — |
| 2026-08-18 | RHONDA M. CHICKO | Chief Financial Officer | M | — | — |
| 2026-07-20 | Peter M Hecht | Director | C | — | — |
| 2025-08-11 | RHONDA M. CHICKO | Chief Financial Officer | A | — | — |
| 2025-03-27 | Michael J Higgins | Director | A | — | — |
| 2025-03-27 | Peter M Hecht | Director | A | — | — |
| 2024-11-25 | Slate Path Capital LP | 10%+ Owner | Sell | — | — |
| 2024-08-07 | Regina Margaret Graul | See Remarks | A | — | — |
| 2024-01-26 | Peter M Hecht | Director | A | — | — |
| 2024-01-26 | Regina Margaret Graul | President | A | — | — |
| 2023-12-04 | ERROL B DESOUZA | Director | A | — | — |
| 2023-12-04 | Steven Hyman | Director | A | — | — |
| 2023-12-04 | Peter M Hecht | Director | A | — | — |
| 2023-12-04 | TERRANCE MCGUIRE | Director | A | — | — |
| 2023-08-11 | TERRANCE MCGUIRE | Director | Sell | — | — |
| 2023-05-22 | Peter M Hecht | Chief Executive Officer | A | — | — |
| 2022-07-27 | Steven Hyman | Director | A | — | — |
| 2022-07-26 | Steven Hyman | Director | A | — | — |
| 2022-06-16 | GEORGE H CONRADES | Director | A | — | — |
| 2022-06-16 | TERRANCE MCGUIRE | Director | A | — | — |
| 2022-06-16 | Ole Isacson | Director | A | — | — |
| 2022-06-16 | ERROL B DESOUZA | Director | A | — | — |
| 2022-06-16 | Michael Mendelsohn | Director | A | — | — |
| 2022-06-16 | Stephanie Lovell | Director | A | — | — |
| 2022-06-16 | Marsha Fanucci | Director | A | — | — |
| 2022-01-24 | Peter M Hecht | Chief Executive Officer | A | — | — |
| 2022-01-24 | Cheryl Gault | Chief Operating Officer | A | — | — |
| 2022-01-24 | Anjeza Gjino | Chief Financial Officer | A | — | — |
| 2022-01-24 | Andreas Busch | Chief Scientific Officer | A | — | — |
| 2021-12-10 | Andreas Busch | Chief Scientific Officer | A | — | — |
| 2021-12-10 | Anjeza Gjino | Chief Financial Officer | A | — | — |
| 2021-12-10 | Cheryl Gault | Chief Operating Officer | A | — | — |
| 2021-06-28 | Marsha Fanucci | Director | A | — | — |
| 2021-06-28 | ERROL B DESOUZA | Director | A | — | — |
| 2021-06-28 | Ole Isacson | Director | A | — | — |
| 2021-06-28 | Stephanie Lovell | Director | A | — | — |
| 2021-06-28 | TERRANCE MCGUIRE | Director | A | — | — |
| 2021-06-28 | Kevin Churchwell | Director | A | — | — |
| 2021-06-28 | Michael Mendelsohn | Director | A | — | — |
| 2021-06-28 | GEORGE H CONRADES | Director | A | — | — |
| 2021-06-07 | Peter M Hecht | Chief Executive Officer | Buy | — | — |
| 2021-06-07 | TERRANCE MCGUIRE | Director | Buy | — | — |
| 2021-06-07 | Slate Path Capital LP | 10%+ Owner | Buy | — | — |
| 2021-05-10 | Peter M Hecht | Chief Executive Officer | Buy | — | — |
| 2021-05-06 | Peter M Hecht | Chief Executive Officer | Buy | — | — |
| 2021-03-01 | Anjeza Gjino | Chief Financial Officer | Sell | — | — |
| 2021-03-01 | Christopher I Wright | Chief Medical Officer | Sell | — | — |
| 2020-12-30 | Mark G Currie | President and CSO | Sell | — | — |
| 2020-11-12 | Andreas Busch | Chief Innovation Officer | Buy | — | — |
| 2020-11-10 | William Huyett | Chief Financial Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 130,037 | — |
| — | See Remarks | 22,307 | — |
| — | Director | 7,143 | — |
| — | Director | 4,391 | — |
| — | Chief Financial Officer | 3,574 | — |
| — | Director | 2,857 | — |
| — | Chief Scientific Officer | 1,819 | — |
| — | President and CSO | 1,797 | — |
| — | Director | 842 | — |
| — | Chief Financial Officer | 483 | — |
| — | Chief Medical Officer | 305 | — |
| — | Chief Financial Officer | 226 | — |
| — | Director | 209 | — |
| — | Director | 121 | — |
| — | Director | 31 | — |
| — | Director | 17 | — |
| — | Director | 17 | — |
| — | Director | 17 | — |
| — | Director | 17 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CYCN quote page; the site-wide leaderboard is on the insider transactions hub.